Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models

HER2–targeted treatments have improved survival rates in HER2+ breast cancer patients, yet poor responsiveness remains a major clinical obstacle. Recently, HER2+ breast cancer cells, both resistant and responsive to HER2–targeted therapies, have demonstrated sensitivity to poly–(ADP–ribose) polymera...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansur, Ameer, Song, Patrick N., Lu, Yun, Burns, Andrew C., Sligh, Luke, Yang, Eddy S., Sorace, Anna G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452700/
https://www.ncbi.nlm.nih.gov/pubmed/37626587
http://dx.doi.org/10.3390/biomedicines11082090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452700/
https://www.ncbi.nlm.nih.gov/pubmed/37626587
http://dx.doi.org/10.3390/biomedicines11082090

Ejemplares similares